Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
Jae-Sung YooJi Hoon KimHee Sun ChoJi Won HanJeong Won JangJong Young ChoiSeung Kew YoonSuho KimJung Suk OhHo Jong ChunPil-Soo SungPublished in: Abdominal radiology (New York) (2024)
Although no significant difference was observed for OS and PFS, the ORR of patients in the HAIC group after the failure of atezo-bev therapy was superior to that of newly diagnosed patients. HAIC may prolong survival in patients with HCC after atezo-bev treatment failure.